{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:42:10Z","timestamp":1781163730279,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T00:00:00Z","timestamp":1466985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GlaxoSmithKline Vaccines Srl"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.vaccine.2016.06.039","type":"journal-article","created":{"date-parts":[[2016,6,26]],"date-time":"2016-06-26T01:31:15Z","timestamp":1466904675000},"page":"4235-4242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Preclinical studies on new proteins as carrier for glycoconjugate vaccines"],"prefix":"10.1016","volume":"34","author":[{"given":"M.","family":"Tontini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Balducci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Micoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Balocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Masignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.06.039_b0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates","volume":"152","author":"Schneerson","year":"1980","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.039_b0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/17460441.2011.609554","article-title":"The design of semi-synthetic and synthetic glycoconjugate vaccines","volume":"6","author":"Costantino","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.vaccine.2016.06.039_b0015","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/cb400423g","article-title":"Recent mechanistic insights on glycoconjugate vaccines and future perspectives","volume":"8","author":"Berti","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2016.06.039_b0020","first-page":"692","article-title":"Men ACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection","volume":"11","author":"Pace","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.vaccine.2016.06.039_b0025","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jama.2007.29-c","article-title":"Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants. A randomized controlled trial","volume":"299","author":"Snape","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2016.06.039_b0030","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00148581-200406040-00004","article-title":"Meningococcal Vaccines","volume":"6","author":"Ruggeberg","year":"2004","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.vaccine.2016.06.039_b0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.vaccine.2008.08.075","article-title":"Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15\u201325 years","volume":"27","author":"Ostergaard","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0040","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/174405a0","article-title":"Detoxification of diphtheria toxin with formaldehyde mixed with an amino-acid","volume":"174","author":"Neum\u00fcller","year":"1954","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.06.039_b0045","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1093\/nar\/12.10.4063","article-title":"The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197","volume":"12","author":"Giannini","year":"1984","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2016.06.039_b0050","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.4049\/jimmunol.145.9.3071","article-title":"Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine","volume":"145","author":"Donnelly","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.06.039_b0055","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix\u2122","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.06.039_b0060","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1086\/527396","article-title":"Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines","volume":"46","author":"Forsgren","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.039_b0065","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.vaccine.2014.01.047","article-title":"Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines","volume":"32","author":"Pobre","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.vaccine.2014.11.026","article-title":"Carrier priming with CRM 197 or diphtheria toxoid has a different impact on the immunogenicity of the respective glycoconjugates: biophysical and immunochemical interpretation","volume":"33","author":"Pecetta","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0075","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1016\/j.vaccine.2013.07.078","article-title":"Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines","volume":"31","author":"Tontini","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0080","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(96)06255-1","article-title":"Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults","volume":"349","author":"Cohen","year":"1997","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2016.06.039_b0090","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/IAI.67.11.5806-5810.1999","article-title":"Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam","volume":"67","author":"Kossacza","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.039_b0095","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1084\/jem.166.5.1510","article-title":"Vi capsular polysacchairde-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.","volume":"166","author":"Szu","year":"1987","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.039_b0100","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/IAI.61.3.1023-1032.1993","article-title":"Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus Type 5 and Type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A","volume":"61","author":"Fattom","year":"1993","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.039_b0105","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1016\/j.vaccine.2015.06.102","article-title":"Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized Phase I study","volume":"33","author":"Hatza","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0110","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K","article-title":"Rationally designed strings of promiscuous CD4+ T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines","volume":"31","author":"Falugi","year":"2001","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2016.06.039_b0115","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1128\/IAI.73.9.5835-5841.2005","article-title":"Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein","volume":"73","author":"Baraldo","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.039_b0120","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1128\/IAI.72.8.4884-4887.2004","article-title":"N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines","volume":"72","author":"Baraldo","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.06.039_b0125","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jit800","article-title":"Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli","volume":"209","author":"Wacker","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.039_b0130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1358\/dot.2011.47.3.1556471","article-title":"New conjugate vaccines for the prevention of pneumococcal disease in developing countries","volume":"47","author":"Ginsburg","year":"2011","journal-title":"Drugs Today"},{"key":"10.1016\/j.vaccine.2016.06.039_b0135","doi-asserted-by":"crossref","first-page":"e46648","DOI":"10.1371\/journal.pone.0046648","article-title":"Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens","volume":"7","author":"Pozzi","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.06.039_b0140","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/toxins6041385","article-title":"Recombinant Clostridium difficile toxin fragments as carrier protein for PSII surface polysaccharide preserve their neutralizing activity","volume":"6","author":"Romano","year":"2014","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2016.06.039_b0145","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.vaccine.2014.12.032","article-title":"A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi","volume":"33","author":"Kotharia","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0150","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1021\/acschembio.5b00247","article-title":"Anti-group B Streptococcus glycan-conjugate vaccines using pilus protein GBS80 as carrier and antigen: comparing lysine and tyrosine-directed conjugation","volume":"10","author":"Nilo","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2016.06.039_b0155","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1016\/j.vaccine.2010.01.012","article-title":"Beta-glucan-CRM197 conjugates as candidates antifungal vaccines","volume":"28","author":"Bromuro","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0160","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0003-2697(66)90275-2","article-title":"Determination of free amino groups in proteins by trinitrobenzensulfonic acid","volume":"14","author":"Habeeb","year":"1966","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2016.06.039_b0165","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0014-5793(79)80019-8","article-title":"Disuccnimidyl esters as bifunctional crosslinking reagents for proteins. Assays with myosin","volume":"102","author":"Hill","year":"1979","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2016.06.039_b0170","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0003-2697(82)90540-1","article-title":"A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimido esters","volume":"126","author":"Miron","year":"1982","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2016.06.039_b0175","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.1016\/j.vaccine.2009.07.036","article-title":"Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages","volume":"27","author":"Broker","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.06.039_b0180","first-page":"19077","article-title":"Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X","volume":"vol. 110","author":"Micoli","year":"2013"},{"key":"10.1016\/j.vaccine.2016.06.039_b0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0003-2697(85)90442-7","article-title":"Measurement of protein using bicinchoninic acid","volume":"150","author":"Smith","year":"1985","journal-title":"Anal Biochem"},{"key":"10.1016\/j.vaccine.2016.06.039_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2016.06.039_b0195","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/nar\/gkn254","article-title":"Immune epitope database analysis resource (IEDB-AR)","volume":"36","author":"Zhang","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.vaccine.2016.06.039_b0200","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1084\/jem.20050749","article-title":"A novel glyco-conjugate vaccine against fungal pathogens","volume":"202","author":"Torosantucci","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.06.039_b0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/07328303.2011.604453","article-title":"Synthesis of Laminarin fragments and evaluation of a \u03b2-(1,3) glucan hexasaccaride-CRM197 conjugate as vaccine candidate against Candida albicans","volume":"30","author":"Adamo","year":"2011","journal-title":"J Carbohydr Chem"},{"key":"10.1016\/j.vaccine.2016.06.039_b0210","doi-asserted-by":"crossref","first-page":"e70365","DOI":"10.1371\/journal.pone.0070365","article-title":"Identification of potential new protein vaccine candidates through pan-surfomic analysis of pneumococcal clinical isolates from adults","volume":"8","author":"Olaya-Abril","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.06.039_b0215","doi-asserted-by":"crossref","first-page":"e36588","DOI":"10.1371\/journal.pone.0036588","article-title":"Protective activity of Streptococcus pneumoniae Spr1875 protein fragments identified using a phage displayed genomic library","volume":"7","author":"Angela Cardaci","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.06.039_b0220","unstructured":"Carrier molecule comprising a spr0096 and a spr2021 antigen, Patent WO2013068949A1, 2013."},{"key":"10.1016\/j.vaccine.2016.06.039_b0225","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/j.vaccine.2016.06.039_b0230","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/erv.10.147","article-title":"Menveo\u00ae: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y","volume":"10","author":"Cooper","year":"2011","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2016.06.039_b0235","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2016.06.039_b0240","doi-asserted-by":"crossref","first-page":"S2110","DOI":"10.1016\/S0264-410X(03)00209-3","article-title":"The value of vaccines","volume":"21","author":"Masignani","year":"2003","journal-title":"Vaccine"}],"updated-by":[{"DOI":"10.1016\/j.vaccine.2017.03.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T00:00:00Z","timestamp":1493683200000}}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16304637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T21:00:12Z","timestamp":1692392412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16304637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":48,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0264410X16304637"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.039","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.vaccine.2017.03.011","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical studies on new proteins as carrier for glycoconjugate vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 GSK. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}